Icon

Tabrecta - (150 and 200 mg ; Tablet)

Capmatinib Novartis
150 and 200 mg ; Tablet
Less Than $1000 mn
None None
Less Than 5
None
None None
TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Yes
Tabrecta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* *******
  1. *** *, **** : * **** ** ** ***** *** ***** ** *** ***.

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.